Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial

Trial Profile

Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2014

At a glance

  • Drugs BA 015 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jan 2013 Planned end date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 07 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Oct 2012 Results were reported at the 37th Congress of the European Society of Medical Oncology (ESMO-2012), according to a BioAlliance Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top